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Abstract
Decision makers increasingly require cost-effectiveness evidence to inform resource allocation and the need for systematic 
reviews of economic evaluations (SREEs) has grown accordingly. The objective of this article is to describe current practice 
and identify unique challenges in conducting and reporting SREEs. Current guideline documents for SREEs were consulted 
and summarised. A rapid review of English-language SREEs, using MEDLINE and EMBASE, published in 2017/2018, 
containing at least 20 studies was undertaken to describe current practice. Information on data extraction methods, quality 
assessment (QA) tools and reporting methods were narratively summarised. Lessons learned from a recently conducted 
SREE of weight loss interventions for severely obese adults were discussed. Sixty-three publications were included in the 
rapid review. Substantial heterogeneity in review methods, reporting standards and QA approaches was evident. Our recently 
conducted SREE on weight loss interventions identified scope to improve process efficiency, opportunity for more transparent 
and succinct reporting, and potential to improve consistency of QA. Practical solutions may include (1) using pre-piloted 
data extraction forms linked explicitly to results tables; (2) consistently reporting on key assumptions and sensitivity analyses 
that drive results; and (3) using checklists that include topic-specific items where relevant and allow reviewers to distinguish 
between reporting, justification and QA. The lack of a mutually agreed, standardised set of best practice guidelines has led 
to substantial heterogeneity in the conduct and reporting of SREEs. Future work is required to standardise the approach to 
conducting SREEs so that they can generate efficient, timely and relevant evidence to support decision-making. We suggest 
only data extracting information that will be reported, focusing discussion around the key drivers of cost-effectiveness, and 
improving consistency in QA by distinguishing between what is reported, justified by authors and deemed appropriate by 
the reviewer.
Key Points for Decision Makers 
The need for systematic reviews of economic evaluation 
evidence has grown recently and is expected to continue 
to grow into the future as more decision-making bodies 
explicitly consider the value for money of new health-
care interventions.
A standardised approach on how to best summarise 
cost-effectiveness evidence is lacking and a set of mutu-
ally agreed best practice recommendations is required 
to improve the efficiency, relevance and transparency of 
future reviews.
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1 Introduction
Economic evaluations (EEs) are an increasingly common 
requirement for evidence-based resource allocation decisions 
[1–3]. Systematic reviews of clinical effectiveness, utilities 
and costs are often used to populate cost-effectiveness mod-
els. However, systematic reviews of EEs (SREEs) are rarely 
used to provide cost-effectiveness evidence directly to policy 
makers.
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The rationale behind SREEs and clinical-effectiveness 
reviews are similar. Decision makers are faced with often 
unmanageable amounts of information, from multiple dif-
ferent sources, often making conflicting value arguments. 
SREEs can provide an efficient mechanism to synthesise, 
report and disseminate the available cost-effectiveness evi-
dence to answer a specific value question. By identifying 
where sufficient research is available to answer a policy 
question, and by demonstrating where the key research 
gaps lie, SREEs can help to avoid research waste, allowing 
funders and researchers to deploy their efforts more effi-
ciently, where the greatest marginal gains of investment can 
be realised.
Despite their obvious benefit, there are many challenges 
to conducting a meaningful SREE. Some challenges are 
also encountered in clinical-effectiveness systematic 
reviews (e.g. heterogeneity in populations, study designs, 
methodology and consistency of outcome reporting), but 
others are unique to SREEs, and may be a limiting factor 
in their more widespread adoption. There is an extra layer 
of complexity in synthesising economic evidence due to 
the substantial variability across, and often within, different 
country-specific healthcare systems in terms of the pay-
ment for and delivery of healthcare. Therefore, different 
modelling assumptions (care pathways, time horizons, dis-
counting procedures), analysis perspectives (person payer, 
insurance provider, government payer) or evaluation frame-
works (cost-utility, cost-effectiveness, cost-benefit or cost-
comparison) are needed to satisfy local decision-making 
requirements. Generalisability of economic evidence is dif-
ficult due to fluctuation of costs (due to inflation, costing 
practices, changes in payment for healthcare) and variation 
in society’s valuation of health outcomes across countries 
and over time [4]. The substantial heterogeneity means that 
quantitative evidence synthesis using meta-analysis is often 
not possible and so narrative summaries of the evidence 
are usually required. Anderson [5] discussed the value of 
conducting SREEs, and how useful they are for answering 
specific policy questions, and suggest that the conduct of 
a SREE should be explicitly justified by reviewers, with 
a clear description of its purpose. Sculpher et al. [6] and 
Welte et al. [7] suggested 26 and 14 factors, respectively, 
that need to be transferable to another setting, in order for 
the EE to be relevant for decision-making. Boulenger et al. 
[8] pointed out that in order to be fully transferable, the 
economic model used would have to be tested with the data 
required for the specific context. The aim of this paper is 
to complement the existing research. We focus on how to 
address the challenges of a SREE given that the decision 
has been made to conduct one.
Large SREEs are resource intensive to complete and can 
generate large volumes of information, with much scope for 
inefficiencies in the process. This paper describes the current 
state of practice, using a rapid review of recently published 
SREEs, and discusses some of the unique challenges of 
conducting a SREE using a case study of weight-loss inter-
ventions. We envisage that the combination of a narrative 
review of current SREE practice and insights gained through 
our own large SREE experience will prove useful for future 
reviewers of EE evidence.
2  Objectives
The objectives of this paper are to describe the current state 
of practice, identify and discuss the key challenges of con-
ducting SREEs, and suggest methods for improvement based 
on reflection of our experiences conducting a large SREE 
for weight loss interventions for severely obese adults (body 
mass index [BMI] ≥ 35 kg/m2) as part of the REBALANCE 
(REview of Behaviour And Lifestyle interventions for severe 
obesity: AN evidenCE synthesis) project [9].
3  Methods
3.1  The REBALANCE Case Study
The REBALANCE project included a SREE for weight 
management (weight-loss and weight maintenance) pro-
grammes (WMPs), including diet and lifestyle interventions, 
behaviour change interventions, drug interventions and bari-
atric surgery for adults aged ≥ 18 years with severe obesity 
(BMI ≥ 35 kg/m2).
Full details of the methods, including a PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses) diagram, and results are reported elsewhere [9]. 
Briefly, studies conducted alongside trials and decision mod-
els that compared costs and outcomes in a single framework 
were included. A bespoke predefined online data extraction 
form was used to collect all reported economic data. Stud-
ies were assessed against the Drummond and Jefferson [10] 
and Philips et al. [11] checklists for trial-based and decision 
modelling studies, respectively.
Forty-six studies were included and narratively synthe-
sised by modality of intervention (bariatric surgery [n = 27], 
lifestyle WMPs [n = 16] and orlistat [n = 3]) and EE type 
(within trial and decision modelling studies). Surgery was 
always deemed cost-effective due to long-term weight loss, 
but results for non-surgical WMPs were uncertain. The 
validity of the findings was dependent on the methodological 
quality of the studies. Common quality concerns were (1) a 
minority of non-surgical WMPs conducted long-term deci-
sion modelling to capture the full impact of obesity-related 
disease; (2) cost and utility implications from surgery-related 
complications were rarely included; and (3) weight regain 
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assumptions were rarely described or adequately tested in 
sensitivity analysis (SA).
3.2  Rapid Review of Systematic Reviews 
of Economic Evaluations (SREEs)
A rapid review of large (≥ 20 studies assessed) SREEs 
published in 2017 and 2018, recorded in two databases 
(MEDLINE and EMBASE) was undertaken. As the aim 
of the rapid review was to describe the most recent prac-
tice for conducting large SREEs, only the most recently 
published studies were included. The purpose of the rapid 
review was to provide context of current practice and it 
was not intended to be an exhaustive assessment of the 
literature. The search strategy, provided in Appendix 1.1 
in the Electronic Supplementary Material combined filters 
for EE studies with a title search for “systematic review”. 
Full-text, freely accessible articles published in the English 
language were included. Systematic reviews of cost-only 
studies, methods applications, conference abstracts and 
letters were all excluded. Abstract and full-text screening 
was conducted by one health economist using a predefined 
data extraction form in Microsoft  Excel® (Microsoft Corp., 
Redmond, WA, USA). Information was collected on the 
number of items stated to be data extracted, actual number 
of items reported, quality assessment (QA) details, if any, 
and any visualisation of the results (e.g. graphical repre-
sentation). A narrative discussion of current practice is 
provided, supplemented with simple frequency reporting 
of key information. The SREEs identified were not other-
wise quality assessed.
After removal of duplicates, the search strategy identified 
1663 potentially relevant titles. After review of titles and 
abstracts, 189 studies remained. A further 113 were excluded 
either because the full text was not retrievable or the article 
no longer met the inclusion/exclusion criteria (leaving 76 
studies). A further 13 reviews failed to report the number of 
studies in the abstract and were also excluded. Sixty-three 
full-text papers were retrieved, analysed and data extracted. 
The median number of studies included in each SREE was 
34 (range 21–115). The PRISMA diagram is presented in 
Appendix 1.2 in the Electronic Supplementary Material.
3.3  Review of Current Guidelines
Current guidelines for the conduct of SREEs were narra-
tively summarised to identify current best practice methods. 
Details of some of the most widely cited current guidelines 
(e.g. Cochrane guidelines) were obtained from a hand search 
of reference lists of the identified studies from our rapid 
review of reviews and the reference lists of other published 
SREEs. The guidelines focused on were those that provided 
guidance on the methods of data extraction and reporting.
3.4  Description and Summary of the Key Challenges 
of Completing a SREE
The results that follow describe the experiences of conduct-
ing the REBALANCE SREE and the challenges encoun-
tered and lessons learned, and make recommendations for 
future practice across three main areas of the review pro-
cess: (1) data extraction: what and how much data should 
be extracted, and how do we extract data efficiently; (2) evi-
dence synthesis: how can we synthesise cost-effectiveness 
evidence in a meaningful manner, that is informative for 
decision makers, when meta-analysis is not possible; and (3) 
QA: how we can better quality assess studies, in a manner 
that is more consistent with the research question/disease 
area for review, and are there ways in which the relevance, 
usability and transparency of commonly used QA and 
reporting checklists can be improved? The experiences of 
the REBALANCE study are supplemented with the findings 
from the rapid review of current practice where appropriate.
4  Results
4.1  Data Extraction
4.1.1  Current Guidelines
The Centre for Reviews and Dissemination (CRD) provides 
broad guidance for undertaking SREEs, including advice to 
use predefined and piloted data extraction forms [12]. The 
guidance suggests categories of data (e.g. study results) but 
provides limited further guidance for reviewers. The Joanna 
Briggs Institute Reviewers’ Manual 2014 includes a pre-
specified list of items to extract [13]. Van Mastrigt et al. [14] 
recommend piloting a data extraction form for thorough-
ness. Wijnen et al. [15] recommend a list of 35 items for data 
extraction and illustrative dummy tables for study charac-
teristics and study results; however, they emphasise that the 
extracted items should reflect the most important items, not 
just the items in the template provided. There is undoubtedly 
a trade-off between the efficiency gains of bespoke extraction 
and the cross-review consistency of a predefined shopping list 
of data extraction items that must be considered by reviewers. 
Overall, of the few guidelines mentioned here, current guid-
ance documents provide a range of advice to reviewers, gen-
erating marked differences in approaches taken across SREEs.
4.1.2  Findings from the Rapid Review
Table 1 shows the results from the rapid review on data 
extraction methodology. Studies included in the rapid review 
are presented in Appendix 1.3 in the Electronic Supplemen-
tary Material.
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Our findings are similar to those of Luhnen et al. [16, 17], 
who found that 32% and 44% of studies used a standardised 
data extraction form, respectively. It is concerning that many 
studies failed to provide any details on the data extraction 
method [16]. Where detailed information was provided, 
some studies failed to report on all the data extraction items. 
Such reviews lack transparency and may be inefficient, as 
reviewers are extracting more data than necessary.
4.1.3  Lessons Learned from REBALANCE
The majority of data items extracted from the REBAL-
ANCE review were not reported. The decision on what data 
to report was based on text constraints, despite the ability 
to provide data in online appendices, and striking a balance 
between reporting relevant informative data and information 
overload. On reflection, the process was highly inefficient. A 
helpful and more efficient approach would have been to use a 
predefined dummy table of results to design the data extrac-
tion form. The decision should be based on what is relevant 
to the research question and what is needed for reporting.
Another challenge from the REBALANCE review was 
that many studies reported multiple SAs. We extracted all 
SA results across all studies. However, a more useful and 
efficient approach may be to predefine the most important 
SA that might be expected to impact on the incremental cost-
effectiveness ratio (ICER). For example, in obesity studies, 
this might include the rate of weight regain after interven-
tion delivery.
Table 2 provides a suggested template that could be used 
for data extraction of results information, explicitly linked to 
result reporting. The suggested template is for cost-effective-
ness results only. Study characteristics such as methodologi-
cal details would also need to be data extracted.
To ensure relevance, the form should be piloted on a 
small number of studies to resolve any remaining issues 
and ensure data collection items are sensible, complete and 
relevant.
The REBALANCE study used an online data extraction 
form, with automated checks to help minimise extraction 
errors and flag disagreement amongst reviewers. Combining 
the positive experience of using online forms with the les-
sons learned, selection of relevant information for extraction 
could substantially improve the efficiency of the review 
process.
4.2  Reporting and Presentation 
of Cost‑Effectiveness Results
4.2.1  Current Guidelines
Reporting guidance focuses on providing transparent cost-
effectiveness information. This includes reporting study 
methods such as perspective, population, time horizon, 
effectiveness source, benefit measurement, study type, model 
type, SAs (both a list of parameters and range of ICERs), 
and base-case deterministic and probabilistic results [18].
4.2.2  Findings from the Rapid Review
Table 3 describes the methods used for reporting study 
results in the rapid review.
Encouragingly, the majority of studies followed PRISMA 
recommendations, a key example of how clear guidance can 
improve standardisation of reporting. Visual presentations 
of results can help deliver key messages. However, caution 
is required as there is a risk that the reader may incorrectly 
compare results across studies without considering the 
appropriate caveats regarding heterogeneity. Luhnen et al. 
[17] also found that most studies conducted a narrative syn-
thesis of results and did not use a graphical representation.
4.2.3  Lessons Learned from REBALANCE
Base-case ICERs were reported alongside minimum and 
maximum ICERs from SA for each study. However, the 
reporting could have been more informative and transparent 
if a template such as that suggested in Table 2 was used to 
derive the proportion of studies that conducted each key SA 
and the associated impact on the base-case ICER. For exam-
ple, the REBALANCE de novo model found that results 
were highly sensitive to weight regain assumptions. How-
ever, only a minority of studies in the SREE specified their 
regain assumptions and fewer still tested them in a SA [9]. It 
is essential that SREEs identify the most important assump-
tions, and extract concise information on the impact of these 
assumptions on results. This would help to describe the true 
Table 1  Rapid review findings 
on data extraction methods Data extraction method Proportion of studies [n 
(%)]
Detailed specification of data items provided 31 (49)
Qualitative summary of method, including statement that a predefined or standardised data 
extraction form was used without detailed description of the items
24 (38)
No details 8 (13)
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uncertainty in cost-effectiveness results. We did not quan-
titatively synthesise the ICERs obtained from the REBAL-
ANCE review because of the significant heterogeneity 
across studies in terms of methodology, healthcare systems 
and definitions of interventions/comparators. Synthesising 
ICERs would run the risk of misinterpretation of the results, 
e.g. by comparing all ICERs to the same country-specific 
cost-effectiveness threshold.
4.3  Quality Assessment/Reporting Checklists
4.3.1  Current Guidelines
Multiple reporting and QA checklists exist and continue to 
develop over time. Currently, Cochrane recommends the 
Drummond and Jefferson [10] and Evers et al. [19] check-
lists for EEs conducted alongside single effectiveness studies 
and the Philips et al. [11] checklist for decision-analytical 
models [20].
4.3.2  Findings from the Rapid Review
Table 4 describes the different checklists identified as part 
of the rapid review, including a description of its general use 
(decision models or EEs alongside single effectiveness stud-
ies) and whether it can be considered a reporting standard 
or true QA tool.
Similarly to Luhnen et al. [16, 17], we find that the most 
popular checklist was the Drummond and Jefferson [10] 
checklist. It is concerning that approximately one-third of 
SREEs have not conducted any formal QA. Luhnen et al. 
[16] raised similar concerns, finding that about half of the 
health technology assessment (HTA) reports and one-third 
of the rapid reports did not provide a formal QA [16]. It 
is also concerning that many SREEs claim to have con-
ducted QA, but further reading identifies that in fact report-
ing standards such as the CHEERS (Consolidated Health 
Economic Evaluation Reporting Standards) statement were 
used instead [22]. Furthermore, it was clear from the rapid 
review that many studies inappropriately used the same QA 
tool for model-based and trial-based EEs. None of the avail-
able QA tools contain sufficiently detailed questions to judge 
the quality of both study types. Furthermore, none of the 
checklists in Table 4 allow the reviewer to explicitly dis-
tinguish between reporting checks, justifications provided 
for assumptions and QA based on the reviewer’s expertise. 
Reporting standards and QA tools are often incorrectly used 
inter-changeably in the assessment of EE studies.
In addition, some checklists include items containing 
multiple component subquestions. For example, were the 
assumptions about long-term health effects reported and 
justified? Or were costs and QALYs discounted appropri-
ately? Such ambiguity can generate inconsistency among Ta
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reviewers. Walker et al. [27] reviewed ten checklists and 
found that they performed poorly in terms of inter-rater relia-
bility. Time spent reconciling differences in opinion amongst 
reviewers could be minimised if questions were clearer.
4.3.3  Lessons Learned from REBALANCE
The lack of clarity in QA checklists made it challenging to 
consistently quality assess a large number of studies, with 
potential for within- and between-reviewer discrepancies. 
On reflection, the QA tools [10, 11] used in the REBAL-
ANCE study did not always reflect the actual quality of the 
study. Some studies scored highly, whereas in fact they were 
judged by the reviewers to be of poor quality. For example, 
weight regain assumptions were poorly reported and justified 
by many studies in the REBALANCE SREE, yet they often 
scored highly using the checklists. One suggestion might be 
to adapt QA tools to include topic-specific bolt-on items that 
are pertinent to assessing the quality of EEs in specific topic 
areas, such as obesity.
Luhnen et al. [16] identified some examples of the use 
of bolt-on items to standard checklists, including adaptions 
to the Drummond and Jefferson [10] checklist by using 
additional QA criteria, e.g. based on a policy brief from 
Table 3  Method of reporting 
study results identified in the 
rapid review
EE economic evaluation, ICER incremental cost-effectiveness ratio, PRISMA Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses
a Some studies used different methods to present the study results; therefore, the numbers do not add up to 
100%
Method Proportion of 
studies [n (%)]a
PRISMA/flow diagram 59 (94)
Trend graph of EE publications over time 7 (11)
Matrix 1 (2)
Graphical representation of the costs included or ICERs depicted 6 (10)
Figure of a typical model structure identified 1 (2)
Links between the included published models 1 (2)
Bar chart presenting study characteristics/study results 13 (21)
Reported key indicator(s) of cost-effectiveness 10 (16)
Table 4  Reporting standards and quality assessment checklists
CHEERS Consolidated Health Economic Evaluation Reporting Standards, DM decision model, NICE National Institute for health and Care 
Excellence, QA quality assessment, QHES Quality of Health Economic Studies, SES single effectiveness study, SIGN Scottish Intercollegiate 
Guidelines Network
a Some studies included multiple checklists and some did not conduct a QA; therefore, the numbers to not add up to 100%
b On the NICE website, this checklist is not recommended for assessment of study quality or reporting quality [23]
c The SIGN checklist is based on the Drummond and Jefferson [10] checklist
d The columns ‘Reported’, ‘Justified’ and ‘Quality assessed by the reviewer’ refer to whether the checklists specifically asked about whether the 
item was reported, justified and/or quality assessed by the reviewer
Checklist No. of items DM SES Reportedd Justifiedd Quality assessed 
by the  reviewerd
No. of studies 
in rapid review 
[n (%)]a
Philips et al. [11] 57 X X X 7 (11)
Drummond and Jefferson [10] 35 X X X 16 (25)
Evers et al. [19] 19 X X X 8 (13)
QHES [21] 16 X X X 8 (13)
CHEERS [22] 24 X X X 11 (17)
NICEb [23] 20 X X X 2 (3)
European Network of Health Economic Evaluation 
Databases [24]
42 X X X 1 (2)
Stuhldreher et al. [25] 22 X X 1 (2)
SIGNc [26] 12 X X X 1 (2)
No QA tool appears to have been used in the study 18 (29)
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the Campbell Collaboration on economic methods [28] or 
WHO guidance on EEs for immunisation programmes [29]. 
Checklist adaptability can improve a checklist when it is able 
to better reflect the quality of the studies. The usefulness of 
the QA results depends on the quality and applicability of 
the QA checklists themselves.
5  Discussion
SREEs are growing in popularity, but the methodology is 
still developing. Our rapid review of reviews identifies some 
concerns regarding the lack of detail on the data extraction 
method, the potential risk of misinterpretation of the visu-
ally represented results and the lack of use of a formal QA. 
Luhnen et al. [17] have identified many similar concerns in 
their recently completed review, conducted in parallel with 
our work. Our study compliments the review of Luhnen 
et al. [17] by describing the lessons learned from our own 
recently completed large SREE as part of the REBALANCE 
study. We identify some solutions to common problems and 
make some practical recommendations for future practice to 
streamline and improve the review process.
There is limited consensus around guidelines to standard-
ise practice. Evidence from the rapid review, and reflection 
on the REBALANCE SREE experience indicate scope to 
improve review efficiency. One suggestion to improve con-
sistency of reporting and identification of important results 
is to link the results data extracted to the results reported, 
focusing on the most important, predefined SAs. Instead of 
data extracting all potentially relevant data, we recommend 
data extracting only what will be used for the report. For 
example, for the results, we recommend extracting only the 
data demonstrated in Table 2, i.e. not extract all SA, but 
only focus on predefined key drivers of cost-effectiveness 
and report those. This leads to time efficiency, while at the 
same time directing the reader to the most important drivers 
of cost-effectiveness.
QA checklists appear to lack clarity in their questions, 
and there appears to be substantial incorrect use of report-
ing checklists to assess EE quality. A helpful amendment to 
current instruments may be to simply distinguish between 
(1) what is reported; (2) whether it was justified by the 
authors; and (3) whether it was deemed of appropriate qual-
ity as judged by the reviewers. In addition, it may be helpful 
to supplement a core set of QA questions (e.g. discount-
ing, time horizon, etc.) with topic-specific bolt-on items. 
For example, in obesity SREEs this might include ques-
tions about weight regain assumptions, appropriateness and 
completeness of the modelled obesity related diseases, and 
incorporation of costs and disutility associated with bariatric 
surgery complications. These bolt-on items should be SREE 
specific, agreed in advance of data extraction and linked 
where possible to the important analyses specified for data 
extraction (Table 2). To improve consistency in QA, it is 
important that journals and the health economic community 
adopt clear consensus guidelines for the conduct of SREE. 
This should be a priority of future research.
The SREE should aim to provide information on whether 
an intervention is cost-effective, but should be transparent 
about the likely significant heterogeneity across the included 
studies. Reviews should therefore provide ranges of plausi-
ble ICERs, alongside appropriate caveats about their gener-
alisability across settings. SREEs should also provide key 
information from the included studies, including how they 
differ, in order to make the SREE as transparent and inform-
ative as possible. We caution against converting ICERs to 
a common currency as this might lead to misinterpretation 
of the results due to heterogeneity across healthcare sys-
tems. It is important to acknowledge the differences across 
studies and to comment on what impacts their generalis-
ability [6, 7]. The process of transparency can be helped 
using graphical representation of results, but the associated 
caveats around heterogeneity should be clearly flagged. If 
applicable, the review should identify a subset of studies that 
answer the research question for the review. For example, 
if it is a review commissioned by the National Institute for 
Health and Care Excellence (NICE), then the review should 
identify the whole set of evidence, but also narratively (or 
otherwise) describe the subset of studies that are directly 
applicable to the research question. A SREE could also be 
useful in identifying decision models that could be adapted 
to address a specific research question, as opposed to build-
ing the de novo model from scratch. Trial-based EEs might 
not be able to answer the research questions because they 
are typically of short duration and based on a single study.
Current process guidelines for SREEs may provide some 
helpful advice, but further detailed consensus based guid-
ance is needed. Shemilt et al. [30] argued that the Cochrane 
SREE methodology varies and has inconsistent reporting 
of the results. To improve transparency, it is good prac-
tice to publish the systematic review protocol [14], as was 
done with the REBALANCE review [31]. Guidelines on 
the conduct of the search for EE is well-developed (see the 
Cochrane Handbook for Systematic Reviews of Interven-
tions [20]). Van Mastrigt et al. [14] also provide a step-by-
step guide for reviewers developing their search. However, 
reviewers are faced with many challenges unique to SREEs 
that are not currently covered by guidance documents, lead-
ing to inefficient and inconsistent reviews.
A number of other studies have attempted to address 
some challenges of conducting SREEs. Pignone et al. [32] 
suggested ways forward for the SREE-specific challenges 
such as critically appraising studies and presenting results. 
For example, they recommend some key features to be crit-
ically appraised (including model type, perspective, costs 
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included and others) and they developed a set of guidelines 
for improving SREE [32], suggesting that ICERs for each 
comparison should be reported along with the input param-
eters to better understand the results. Different methods have 
been suggested on how to present the result in a simpli-
fied manner such as the three-by-three dominance ranking 
matrix (DRM) tool [14, 33], harvest plot [34] and hierar-
chical method [16, 35]. Others have discussed the use of 
the QA tools. Ramos et al. [36] highlighted the complexity 
and impracticality of checklists and suggested a 5-dimen-
sion framework on good practice procedure in modelling. 
Gomersall et al. [33] suggested separating multi-component 
questions into single items to avoid ambiguity.
There is still no consensus in the health economics com-
munity on which guidelines to follow when conducting 
SREEs. Consistency in SREE methodology would be highly 
beneficial; however, this is not possible without researchers 
or journals coming together and agreeing on a standardised 
approach to SREE.
Whilst we are transparent with regards to our rapid review 
methodology, it comes with some limitations. Our rapid 
review was confined to publication years 2017–2018 and 
only SREEs that included 20 studies or more. The review 
should therefore be considered as a description of current 
practice, rather than an exhaustive systematic assessment. 
The number of items in the predefined data extraction list 
and the number of reported items are subject to some uncer-
tainty because often when the studies listed items to data 
extract, items were summarised, not giving a true picture of 
the predefined listed items versus reported items.
6  Conclusion
SREEs might prove to be challenging to conduct, with some 
studies debating its usefulness [5], but a well-conducted 
SREE is a useful framework for identifying good-quality 
economic evidence, avoiding research waste and identifying 
research priorities to support healthcare decision-making. 
Development of a detailed set of consensus-based guidelines 
for reviewers of EE evidence is a key priority for future 
research. We suggest an efficient approach to data extrac-
tion be taken and only data extract what will be used for the 
report, only report the key SAs (drivers of cost-effective-
ness) in the results table, and improve consistency in the QA 
by distinguishing between what was reported, justified and 
deemed of appropriate standards by the reviewer.
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